KVA 12.1 a novel fully human anti-VISTA antibody clinical trial design in monotherapy and in combination with an anti-PD1 antibody
Thierry Guillaudeux, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 2021 | November, 2021
A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors
Thierry Guillaudeux, PhD, Chief Scientific Officer American Association for Cancer Research (AACR) Annual Meeting 2021 | April, 2021
Highly Potent Fully Human Anti-VISTA Antibodies Efficiently Abrogate the Interaction of VISTA to Its Putative Receptors at Different pH
Thierry Guillaudeux, PhD, Chief Scientific Officer European Society for Medical Oncology (ESMO) Virtual Congress 2020 | December 9, 2020
Highly Potent Fully Human anti-VISTA Antibodies A New Target Checkpoint Inhibitor against Immunosuppressive Myeloid Cells
Thierry Guillaudeux, PhD, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting | November 12, 2020
Highly Potent Fully Human anti-VISTA Antibodies A New Target Checkpoint Inhibitor against Immunosuppressive Myeloid Cells
Thierry Guillaudeux, PhD, Chief Scientific Officer American Association for Cancer Research (AACR) Virtual Special Conference: Tumor Immunology and Immunotherapy | October 19-20, 2020